Thus, anEGFR-SOX2-BCL2L1 pathway may be implicated in cancer cells with wild-type EGFR,whereas the EGFR-FOXO6-SOX2-BIM/BMF pathway we describe is specific for cells thatare dependent on mutant EGFR signals for their survival. The gene discussed is BCL2L11; the disease is cancer.